AI-generated · cited to primary sources · not investment advice · How we research
Anthem Bioscienc
Our verdict on Anthem Bioscienc isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
The company reported EBITDA margins of 44.5% for Q2FY26 and 41.4% for H1FY26, significantly exceeding the 38% target range. (5 exceeded across 5 tracked commitments)
“In terms of revenue growth, it will be in the mid-teens around 15% to 16% is what we will be anticipating to end the year with.”
The company reports that 9MFY26 revenue from Specialty Ingredients (primarily produced at Unit III) is at Rs. 253.5 Cr (INR 2,535 Mn), suggesting the target for the unit is likely to be met or exceeded by year-end. (1 in progress, 2 met across 3 tracked commitments)
“Our idea would be to push this number to say Rs. 100 Cr - Rs. 150 Cr, by which time we would be supplying. This has been our strategy. We don't like to keep our plants vacant.”
The fermentation block at Unit III (NeoAnthem) is still expected to be commissioned by the end of the year. (1 in progress, 2 met across 3 tracked commitments)
“Fermentation 142 kiloliters, we are adding 40 kiloliters more in NeoAnthem, which should also get done in this calendar year.”
Management confirmed the commissioning of the CP7 block (76 kiloliters) in Unit-2 during the last quarter. (3 met, 2 revised across 5 tracked commitments)
“Commissioning of Fermentation block expected by end of the year”
The company is actively scouting for strategic acquisitions in India and abroad.
“Secondly, in terms of acquisitions and growth, apart from our organic growth, which is also substantive, we are not averse to looking at acquisitions, both in India and abroad. We are actively searching.”
See the full cited Management analysis of Anthem Bioscienc
How durable is the business?
The CRDMO segment showed significant expansion, delivering INR 452.7 crores in revenue for Q1 FY26, driven by increased demand for commercialized products from 5-6 key clients. (5 expanding)
“The CRDM business delivered INR452.7 crores revenues out of that... The strong year-on-year growth in this quarter FY26 reflects our CRDM or revenue stream that started ramping up in Q2 of FY25.”
Backward integration for a key intermediate has been completed, which is expected to protect and improve gross margins in future quarters. (5 expanding)
“We source the raw material, manufacture the intermediates, manufacture the API and supply to the customer, and we are not reliant on any external source. The backward integration had helped us in terms of improving our material margins.”
Capacity expansion is progressing with 54 kiloliters added in Q1 FY26. Total custom synthesis expansion of 134 kiloliters is on track for completion this calendar year. (5 expanding)
“Unit 4 is going to be much larger than all the units put together... This will add close to about 365 kiloliters of custom synthesis capacity and 100 kiloliters of fermentation... We are more or less doubling on custom synthesis and adding 50% more on the fermentation side.”
The company is deepening its expertise in high-barrier areas, specifically mentioning 8-9 innovator programs in peptides and the development of a microbial biosimilar for a US customer. (2 expanding)
“4 molecules went commercial. So, still at 6 [in Phase-3]... We currently work with innovator peptides, close to about 8-9 programs.”
The company is expanding its technological moat by commissioning commercial-scale facilities for new modalities like ADCs (Antibody-Drug Conjugates) and Peptides. (2 expanding)
“With respect to the modalities... we have upgraded ourselves from being a lab-scale facility in some of these modalities to commercial-scale facilities. So ADCs... we have now commissioned the new Anthem commercial-scale facility. Peptides also, we have commissioned the commercial-scale facility.”
See the full cited Business Model analysis of Anthem Bioscienc
Where does growth come from?
The CRDMO business is showing strong acceleration, delivering INR 452.7 crores in Q1 FY26, which management notes is a ramp-up from the momentum started in Q2 FY25. (3 accelerating, 1 decelerating, 1 steady across 5 signals)
“The CRDMO business delivered Rs. 513 crores revenues with a growth of 31% YoY basis.”
The pipeline is successfully maturing as molecules move from Phase 3 to commercial status. The commercial portfolio increased from 10 to 12 molecules this quarter. (1 steady, 1 new trend across 2 signals, 1 leading indicator)
“now the late-stage pipeline stands at 10 Phase 3 molecules. Along with that, we work on 100 plus programs on the early-stage side.”
The company is deepening its engagement with global giants, confirming major ongoing engagements with two 'really major' global pharma companies expected to yield results in the near term. (3 new trend across 3 signals)
“However, last year we've had two direct contacts and two direct relationships, which are now, I'm glad to say, growing healthily.”
Margins are showing structural improvement and are accelerating due to complete backward integration and the discontinuation of expensive Chinese intermediate supplies. (2 accelerating across 2 signals)
“The backward integration had helped us in terms of improving our material margins, which has moved up over Q3 and Q4 of last year.”
The pipeline is maturing rapidly; while late-phase molecules decreased from 10 to 6, this is because 4 successfully transitioned to commercial status, indicating a healthy conversion rate. (1 steady across 1 signal)
“The 10 late phase has gone down to 6, because 4 of them have moved to commercial now.”
See the full cited Future Growth analysis of Anthem Bioscienc
What could break the thesis?
The company's net cash position has significantly improved to ₹9,934 Mn as of Sept 30, 2025, up from ₹7,848 Mn in the previous quarter, providing a larger buffer for upcoming capital expenditures. (1 easing, 4 stable, 2 high-severity)
“In Phase 1 of that expansion, and we are looking at investing almost about Rs. 1,200 odd crores across two years, this year FY27 and in FY28. We aim to complete the Phase 1 expansion by March '28 financial year... Unit 4 is going to be much larger than all the units put together.”
The risk is intensifying due to increased political rhetoric regarding drug pricing and potential US tariffs, though management believes their European supply route provides a buffer. (5 intensifying)
“the net expense recognized in "Exceptional Item" amounts to Rs. 243.91 million in the Consolidated financial results... arising due to change in wage definition and gratuity provisions.”
Specialty Ingredients revenue declined 13.1% YoY and 10.7% QoQ, confirming the volatility and potential crowding out by the dominant CRDMO segment. (2 intensifying, 2 easing, 1 stable)
“Q4FY26 Revenue Split: CRDMO 83.9%”
The risk is stable; management acknowledges the need to compete with China, particularly in the emerging GLP-1 space where they aim to be a leading producer. (2 stable, 1 resolved)
“In Korea particularly and in China also, the large companies have built up massive capacities. In that sense, they are ahead of us. There's no denying that. Because there is the upfront investment in large molecules is quite large, so you must be willing to invest billions of dollars for those kinds of capacities.”
Concentration risk is slightly intensifying as CRDMO revenue grew 70.5% YoY, now accounting for 83.8% of total revenue compared to 83.9% in the previous quarter, maintaining a heavy reliance on this single segment. (2 intensifying, 3 easing)
“Q1FY26 Revenue Split: CRDMO 83.8%, Specialty Ingredients 16.2%”
See the full cited Risk analysis of Anthem Bioscienc
Read the full thesis on Anthem Bioscienc
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.